Gathering the record
Relay is organizing the evidence and source boundaries.
Unapproved GHRH-analogue / ghrelin-receptor-agonist blend
A blend of tesamorelin and ipamorelin, usually discussed for body composition and recovery.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Component-only evidence: mature standalone tesamorelin trials and label, plus limited ipamorelin endocrine data and a negative randomized postoperative trial.
Its page must not convert separate component studies into combination proof.
That approval applies to the labeled standalone product for excess abdominal fat in adults with HIV and lipodystrophy, not to a blend or general weight loss.
A hormone peak is not evidence of better body composition, recovery, sleep, or longevity.
This weighs against treating endocrine activity as proof of patient benefit.
GHRHR and GHSR1a convergence is a hypothesis until directly tested.
Risks & unknowns
Relay has not verified a clear pattern of side effects for this compound.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryUnapproved blend — no direct controlled combination evidence located Any blend-specific benefit, safety interaction, dose relationship, product compatibility, stability, sterility, pharmacokinetics, or superiority to either component.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Tesamorelin and ipamorelin have individual human records. Those records do not establish the amount, ratio, schedule, or compatibility of this combination.
What would fill this gap: A direct human protocol for the defined combination and formulation.
Dosing review checked Oct 20, 2026. Additional sources are available below.No route-specific preparation instructions were verified. A different route or product does not supply them.
Starting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
Relay located primary and regulatory research for the two components separately, but no direct human study administering the fixed blend.
Population: No directly studied blend population located
Design: Component-evidence and identity-boundary review
No direct primary administration source was verified for this exact identity.
Mechanisms
Tesamorelin is a GHRH analogue that stimulates pituitary growth-hormone release through GHRHR and has an FDA-approved standalone product for reducing excess abdominal fat in adults with HIV and lipodystrophy. Ipamorelin is a GHSR1a agonist with small acute human pharmacokinetic/pharmacodynamic studies and a randomized postoperative-ileus trial that did not demonstrate the intended clinical benefit. Complementary upstream receptor biology is mechanistically plausible, but no direct controlled evidence located establishes the fixed blend's pharmacokinetics, efficacy, safety, interaction profile, compatibility, reconstitution, or stability. The approved tesamorelin label cannot be transferred to a compounded combination.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
The components have human data; the fixed blend does not.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Direct combination evidence, interaction data, and product standards are absent.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
Tesa/Ipamorelin fixed blend: amounts and schedules describe this route record only.
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Tesamorelin studies did not administer ipamorelin, and ipamorelin studies did not administer tesamorelin. Component routes, findings, and regulated-product instructions cannot create a blend protocol, compatibility claim, or preparation standard. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized placebo-controlled postoperative trial
Adults undergoing bowel surgery
Ipamorelin did not demonstrate the intended postoperative clinical benefit.
Study administration: Intravenous ipamorelin or placebo
Limitations: The indication and route differ from marketed blend discussions, but the negative result is still important component evidence.
Pooled randomized placebo-controlled tesamorelin trials
Adults with HIV and excess abdominal fat
Standalone tesamorelin reduced visceral adipose tissue in its studied HIV-lipodystrophy population.
Study administration: Standalone tesamorelin or placebo
Limitations: This does not evaluate ipamorelin, the blend, general obesity, or healthy users.
Intravenous pharmacokinetic-pharmacodynamic study
Healthy male volunteers
Ipamorelin produced acute GH responses under controlled monitoring.
Study administration: Intravenous ipamorelin infusion
Limitations: Acute IV hormone response does not establish chronic clinical benefit or blend performance.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2025-03-01
2014-10-21 · PMID 25331030 · NCT00672074 · DOI 10.1007/s00384-014-2030-8
2010-09-01 · PMID 20554713 · DOI 10.1210/jc.2010-0490
1999-09-01 · PMID 10496658 · DOI 10.1023/A:1018955126402